ECSP18000689A - Composiciones farmacéuticas sólidas para el tratamiento del vhc - Google Patents

Composiciones farmacéuticas sólidas para el tratamiento del vhc

Info

Publication number
ECSP18000689A
ECSP18000689A ECIEPI2018689A ECPI201800689A ECSP18000689A EC SP18000689 A ECSP18000689 A EC SP18000689A EC IEPI2018689 A ECIEPI2018689 A EC IEPI2018689A EC PI201800689 A ECPI201800689 A EC PI201800689A EC SP18000689 A ECSP18000689 A EC SP18000689A
Authority
EC
Ecuador
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
compound
pharmaceutically acceptable
hcv
Prior art date
Application number
ECIEPI2018689A
Other languages
English (en)
Inventor
Adivaraha Jayasankar
Ping Tong
Katrin Schneider
Ute Lander
Yi Gao
Samuel Kyeremateng
Donghua Zhu
Katherina Asmus
Benedikt Steitz
Marius Naris
Regina Reul
Nancy Sever
Michael Simon
Colleen Garrett
Ulrich Westedt
Harald Hach
Thomas Mueller
Constanze Obermiller
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP18000689A publication Critical patent/ECSP18000689A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas sólidas que comprenden el Compuesto 1 y el Compuesto 2. En una realización, la composición farmacéutica sólida incluye (1) una primera capa que comprende 100 mg de Compuesto 1, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en dispersión sólida amorfa; y (2) una segunda capa que comprende 40 mg de Compuesto 2, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en una dispersión sólida amorfa.
ECIEPI2018689A 2015-06-26 2018-01-08 Composiciones farmacéuticas sólidas para el tratamiento del vhc ECSP18000689A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562185145P 2015-06-26 2015-06-26
US201562186154P 2015-06-29 2015-06-29
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15

Publications (1)

Publication Number Publication Date
ECSP18000689A true ECSP18000689A (es) 2018-03-31

Family

ID=56409187

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI2018689A ECSP18000689A (es) 2015-06-26 2018-01-08 Composiciones farmacéuticas sólidas para el tratamiento del vhc

Country Status (24)

Country Link
US (3) US20160375087A1 (es)
EP (1) EP3313378A1 (es)
JP (2) JP7162425B2 (es)
KR (1) KR102637828B1 (es)
CN (1) CN107920996A (es)
AU (1) AU2016283018C1 (es)
BR (1) BR112017028185A2 (es)
CA (1) CA2990855A1 (es)
CL (1) CL2017003350A1 (es)
CO (1) CO2017013305A2 (es)
CR (1) CR20180030A (es)
DO (1) DOP2017000314A (es)
EA (1) EA201890160A1 (es)
EC (1) ECSP18000689A (es)
HK (1) HK1250627A1 (es)
IL (1) IL256504B (es)
MX (1) MX2018000218A (es)
MY (1) MY192606A (es)
PE (1) PE20180488A1 (es)
PH (1) PH12017502426A1 (es)
RU (2) RU2018102809A (es)
SG (1) SG10202002899VA (es)
WO (1) WO2016210273A1 (es)
ZA (1) ZA201800533B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN108024964B (zh) * 2015-07-17 2022-05-03 艾伯维公司 用于治疗hcv的固体药物组合物
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
ES2414934T3 (es) * 2009-06-11 2013-07-23 Abbvie Bahamas Limited Inhibidores del virus de la Hepatitis C
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
ES2689107T3 (es) * 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
EP3597190A1 (en) * 2012-09-18 2020-01-22 AbbVie Inc. Methods for treating hepatitis c
RS60881B1 (sr) * 2013-03-14 2020-11-30 Abbvie Inc Kombinacija dva antivirusa za lečenje hepatitisa c

Also Published As

Publication number Publication date
KR20180021840A (ko) 2018-03-05
IL256504A (en) 2018-02-28
AU2016283018C1 (en) 2022-03-03
EP3313378A1 (en) 2018-05-02
JP2022177014A (ja) 2022-11-30
CR20180030A (es) 2018-05-24
PH12017502426A1 (en) 2018-07-02
KR102637828B1 (ko) 2024-02-20
CL2017003350A1 (es) 2018-06-22
CO2017013305A2 (es) 2018-05-21
JP2018518517A (ja) 2018-07-12
CN107920996A (zh) 2018-04-17
RU2018102809A (ru) 2019-07-29
RU2021102950A (ru) 2021-03-01
RU2018102809A3 (es) 2019-12-10
SG10202002899VA (en) 2020-05-28
CA2990855A1 (en) 2016-12-29
MX2018000218A (es) 2018-03-08
AU2016283018A1 (en) 2018-01-25
BR112017028185A2 (pt) 2018-09-04
JP7162425B2 (ja) 2022-10-28
ZA201800533B (en) 2018-12-19
US20200282004A1 (en) 2020-09-10
AU2016283018B2 (en) 2021-10-07
PE20180488A1 (es) 2018-03-07
IL256504B (en) 2021-09-30
WO2016210273A1 (en) 2016-12-29
DOP2017000314A (es) 2018-02-15
US20190216882A1 (en) 2019-07-18
US20160375087A1 (en) 2016-12-29
EA201890160A1 (ru) 2018-06-29
HK1250627A1 (zh) 2019-01-11
MY192606A (en) 2022-08-29

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CO6400183A2 (es) Formas de dosificación oral de bendamustina
PE20161385A1 (es) Formulacion inmunosupresora
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
PE20180036A1 (es) Inhibidores de bromodominio
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
ECSP18008411A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
CL2021001244A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2020004545A (es) Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
CL2016003271A1 (es) Métodos para tratar infecciones
UA116464U (uk) Протимікробний засіб
CR20160591A (es) Metodos para tratar infecciones